Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations
Year: 2014
Type: review
Authors: David E. Gerber, Leena Gandhi, Daniel B. Costa
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: non-small cell lung cancer, actionable driver mutations, tyrosine kinase inhibitors, EGFR mutation, ALK rearrangement, crizotinib, gefitinib, erlotinib, afatinib, KRAS, ROS1, RET, BRAF, NTRK1, fibroblast growth factor receptor, precision oncology, predictive biomarkers, progression-free survival
Open Access status: closed
Funder: National Cancer Institute
Award: G2081079141
OpenAlex ID: W2045465355
